SE466134B - Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner - Google Patents

Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner

Info

Publication number: SE466134B
Authority: SE; Sweden
Prior art keywords: gel; water; ehec; surfactant; carrier
Prior art date: 1990-11-22

Application number

SE9003712A

Other languages

English (en)

Swedish (sv)

Other versions

SE9003712L (sv

SE9003712D0 (sv

Inventor

C Bogentoft

Original Assignee

Kabi Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-22

Filing date

1990-11-22

Publication date

1992-01-07

1990-11-22 Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab

1990-11-22 Priority to SE9003712A priority Critical patent/SE466134B/sv

1990-11-22 Publication of SE9003712D0 publication Critical patent/SE9003712D0/xx

1991-10-30 Priority to AU89543/91A priority patent/AU660157B2/en

1991-10-30 Priority to JP4500094A priority patent/JP2694166B2/ja

1991-10-30 Priority to DE69124109T priority patent/DE69124109T2/de

1991-10-30 Priority to AT91920627T priority patent/ATE147273T1/de

1991-10-30 Priority to EP91920627A priority patent/EP0558586B1/en

1991-10-30 Priority to PCT/SE1991/000731 priority patent/WO1992009307A1/en

1991-10-30 Priority to US08/064,141 priority patent/US5492937A/en

1991-10-30 Priority to ES91920627T priority patent/ES2095964T3/es

1991-10-30 Priority to DK91920627.6T priority patent/DK0558586T3/da

1991-10-30 Priority to CA002095728A priority patent/CA2095728C/en

1991-11-22 Priority to PT99593A priority patent/PT99593B/pt

1992-01-07 Publication of SE9003712L publication Critical patent/SE9003712L/xx

1992-01-07 Publication of SE466134B publication Critical patent/SE466134B/sv

1993-05-06 Priority to IE381991A priority patent/IE65545B1/en

1993-05-21 Priority to NO931852A priority patent/NO307816B1/no

1993-05-21 Priority to FI932325A priority patent/FI103714B1/fi

1997-02-12 Priority to GR970400224T priority patent/GR3022536T3/el

Links

239000000203 mixture Substances 0.000 title claims abstract description 80
239000007788 liquid Substances 0.000 title claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
239000004094 surface-active agent Substances 0.000 claims abstract description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
229920003086 cellulose ether Polymers 0.000 claims abstract description 32
239000013543 active substance Substances 0.000 claims abstract description 9
230000036760 body temperature Effects 0.000 claims abstract description 9
239000000654 additive Substances 0.000 claims abstract description 7
229920000896 Ethulose Polymers 0.000 claims description 74
239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 74
235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 74
239000003814 drug Substances 0.000 claims description 39
229940079593 drug Drugs 0.000 claims description 38
239000000651 prodrug Substances 0.000 claims description 11
229940002612 prodrug Drugs 0.000 claims description 11
239000007864 aqueous solution Substances 0.000 claims description 10
210000004877 mucosa Anatomy 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 4
125000001183 hydrocarbyl group Chemical group 0.000 claims description 3
230000000144 pharmacologic effect Effects 0.000 claims 1
238000011200 topical administration Methods 0.000 claims 1
210000004400 mucous membrane Anatomy 0.000 abstract description 2
239000000499 gel Substances 0.000 description 52
239000000243 solution Substances 0.000 description 33
229920000642 polymer Polymers 0.000 description 28
238000012360 testing method Methods 0.000 description 26
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
-1 poly(oxyethylene) Polymers 0.000 description 17
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 16
235000019333 sodium laurylsulphate Nutrition 0.000 description 15
150000003839 salts Chemical class 0.000 description 14
102000004877 Insulin Human genes 0.000 description 12
108090001061 Insulin Proteins 0.000 description 12
229940125396 insulin Drugs 0.000 description 12
238000000338 in vitro Methods 0.000 description 11
210000003097 mucus Anatomy 0.000 description 10
206010013781 dry mouth Diseases 0.000 description 9
239000000523 sample Substances 0.000 description 9
210000004051 gastric juice Anatomy 0.000 description 8
238000000034 method Methods 0.000 description 8
208000005946 Xerostomia Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000001879 gelation Methods 0.000 description 7
239000002563 ionic surfactant Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000000227 bioadhesive Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
229920002678 cellulose Polymers 0.000 description 6
239000001913 cellulose Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 5
229920002125 Sokalan® Polymers 0.000 description 5
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
239000001768 carboxy methyl cellulose Substances 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
238000012377 drug delivery Methods 0.000 description 5
230000001050 lubricating effect Effects 0.000 description 5
238000005259 measurement Methods 0.000 description 5
210000003296 saliva Anatomy 0.000 description 5
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 5
229960000401 tranexamic acid Drugs 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
108010063954 Mucins Proteins 0.000 description 4
102000015728 Mucins Human genes 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000008103 glucose Substances 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000000693 micelle Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 3
239000000120 Artificial Saliva Substances 0.000 description 3
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 3
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
239000000924 antiasthmatic agent Substances 0.000 description 3
230000035587 bioadhesion Effects 0.000 description 3
239000006196 drop Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000002500 effect on skin Effects 0.000 description 3
239000003792 electrolyte Substances 0.000 description 3
238000011067 equilibration Methods 0.000 description 3
235000011389 fruit/vegetable juice Nutrition 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000005191 phase separation Methods 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011775 sodium fluoride Substances 0.000 description 3
235000013024 sodium fluoride Nutrition 0.000 description 3
229960000278 theophylline Drugs 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
230000001088 anti-asthma Effects 0.000 description 2
230000000675 anti-caries Effects 0.000 description 2
230000003178 anti-diabetic effect Effects 0.000 description 2
230000000843 anti-fungal effect Effects 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical class CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
229960003237 betaine Drugs 0.000 description 2
229960001927 cetylpyridinium chloride Drugs 0.000 description 2
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000002439 hemostatic effect Effects 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
239000002324 mouth wash Substances 0.000 description 2
229940051866 mouthwash Drugs 0.000 description 2
230000003232 mucoadhesive effect Effects 0.000 description 2
ZBJVLWIYKOAYQH-UHFFFAOYSA-N naphthalen-2-yl 2-hydroxybenzoate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=C(C=CC=C2)C2=C1 ZBJVLWIYKOAYQH-UHFFFAOYSA-N 0.000 description 2
229960001180 norfloxacin Drugs 0.000 description 2
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000012088 reference solution Substances 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
239000012488 sample solution Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229940035636 somatostatin and analogues Drugs 0.000 description 2
229960004605 timolol Drugs 0.000 description 2
229960005221 timolol maleate Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
FROLUYNBHPUZQU-IIZJPUEISA-N (2R,3R,4S,5R)-2-(hydroxymethyl)-6-[3-[3-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropoxy]propoxy]oxane-3,4,5-triol Chemical compound OC[C@H]1OC(OCCCOCCCOC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O FROLUYNBHPUZQU-IIZJPUEISA-N 0.000 description 1
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical class CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
108010009066 Gastric Mucins Proteins 0.000 description 1
102000009338 Gastric Mucins Human genes 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical class CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
206010028111 Mucosal dryness Diseases 0.000 description 1
IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000208125 Nicotiana Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010019160 Pancreatin Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
CQTULTPVJKCOMH-UHFFFAOYSA-L S(=O)(=O)([O-])[O-].C(CCCCCCCCCCC)C1CO1.[Na+].[Na+] Chemical compound S(=O)(=O)([O-])[O-].C(CCCCCCCCCCC)C1CO1.[Na+].[Na+] CQTULTPVJKCOMH-UHFFFAOYSA-L 0.000 description 1
208000026375 Salivary gland disease Diseases 0.000 description 1
206010040628 Sialoadenitis Diseases 0.000 description 1
229930192786 Sisomicin Natural products 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010048222 Xerosis Diseases 0.000 description 1
UKSMMIUPVQTUDZ-UHFFFAOYSA-M [Na+].CCCCCCCCCCCCOP([O-])=O Chemical compound [Na+].CCCCCCCCCCCCOP([O-])=O UKSMMIUPVQTUDZ-UHFFFAOYSA-M 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229960001466 acetohexamide Drugs 0.000 description 1
VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
125000005600 alkyl phosphonate group Chemical group 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960004821 amikacin Drugs 0.000 description 1
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
229960002469 antazoline Drugs 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001384 anti-glaucoma Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000001857 anti-mycotic effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940030225 antihemorrhagics Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000002543 antimycotic Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
238000003705 background correction Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229960005274 benzocaine Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
229960003150 bupivacaine Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical class CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
229960001761 chlorpropamide Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229940039231 contrast media Drugs 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
229960003572 cyclobenzaprine Drugs 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
125000005131 dialkylammonium group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
229960000616 diflunisal Drugs 0.000 description 1
FBELJLCOAHMRJK-UHFFFAOYSA-L disodium;2,2-bis(2-ethylhexyl)-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCC(CC)CC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CC(CC)CCCC FBELJLCOAHMRJK-UHFFFAOYSA-L 0.000 description 1
YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 1
208000032625 disorder of ear Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
238000005189 flocculation Methods 0.000 description 1
230000016615 flocculation Effects 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000002874 hemostatic agent Substances 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
239000000413 hydrolysate Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical class CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
229960001025 iohexol Drugs 0.000 description 1
125000003010 ionic group Chemical group 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960002418 ivermectin Drugs 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960002409 mepivacaine Drugs 0.000 description 1
INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical class CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
229960000582 mepyramine Drugs 0.000 description 1
229960002330 methocarbamol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
230000004682 mucosal barrier function Effects 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
239000000133 nasal decongestant Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960001528 oxymetazoline Drugs 0.000 description 1
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 1
229960000649 oxyphenbutazone Drugs 0.000 description 1
HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
210000003254 palate Anatomy 0.000 description 1
230000004203 pancreatic function Effects 0.000 description 1
229940055695 pancreatin Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229960001190 pheniramine Drugs 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
229940067626 phosphatidylinositols Drugs 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
150000008106 phosphatidylserines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
229960002386 prazosin hydrochloride Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
108010028349 saliva Orthana Proteins 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
210000003786 sclera Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
208000001050 sialadenitis Diseases 0.000 description 1
229960005456 sisomicin Drugs 0.000 description 1
URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229940120904 succinylcholine chloride Drugs 0.000 description 1
YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960002135 sulfadimidine Drugs 0.000 description 1
ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical compound O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 description 1
229950000244 sulfanilic acid Drugs 0.000 description 1
QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
229960004818 sulfaphenazole Drugs 0.000 description 1
ZQMQGBHQZZQTJE-UHFFFAOYSA-N sulfasymazine Chemical compound CCC1=NC(CC)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZQMQGBHQZZQTJE-UHFFFAOYSA-N 0.000 description 1
229950003748 sulfasymazine Drugs 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000012085 test solution Substances 0.000 description 1
229960002372 tetracaine Drugs 0.000 description 1
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical class CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000008719 thickening Effects 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
229960005371 tolbutamide Drugs 0.000 description 1
229940034610 toothpaste Drugs 0.000 description 1
239000000606 toothpaste Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940072358 xylocaine Drugs 0.000 description 1
KYBJXENQEZJILU-UHFFFAOYSA-N zolamine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CS1 KYBJXENQEZJILU-UHFFFAOYSA-N 0.000 description 1
229950006211 zolamine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Oral & Maxillofacial Surgery (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Birds (AREA)
Medicinal Preparation (AREA)
Colloid Chemistry (AREA)
Pens And Brushes (AREA)
Compositions Of Macromolecular Compounds (AREA)
Dental Preparations (AREA)
Lubricants (AREA)
Rolling Contact Bearings (AREA)
Physical Or Chemical Processes And Apparatus (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

SE9003712A 1990-11-22 1990-11-22 Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner SE466134B (sv)

Priority Applications (16)

Application Number	Priority Date	Filing Date	Title
SE9003712A SE466134B (sv)	1990-11-22	1990-11-22	Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner
JP4500094A JP2694166B2 (ja)	1990-11-22	1991-10-30	ゲル形成液体担体組成物
ES91920627T ES2095964T3 (es)	1990-11-22	1991-10-30	Una composicion de excipiente liquida que forma un gel.
CA002095728A CA2095728C (en)	1990-11-22	1991-10-30	A gel-forming liquid carrier composition
DE69124109T DE69124109T2 (de)	1990-11-22	1991-10-30	Gelbildende flüssigträger-zusammensetzung
AT91920627T ATE147273T1 (de)	1990-11-22	1991-10-30	Gelbildende flüssigträger-zusammensetzung
EP91920627A EP0558586B1 (en)	1990-11-22	1991-10-30	A gel-forming liquid carrier composition
PCT/SE1991/000731 WO1992009307A1 (en)	1990-11-22	1991-10-30	A gel-forming liquid carrier composition
US08/064,141 US5492937A (en)	1990-11-22	1991-10-30	Gel-forming liquid carrier composition
AU89543/91A AU660157B2 (en)	1990-11-22	1991-10-30	A gel-forming liquid carrier composition
DK91920627.6T DK0558586T3 (da)	1990-11-22	1991-10-30	Geldannende flydende bærerpræparat
PT99593A PT99593B (pt)	1990-11-22	1991-11-22	Processo de preparacao de uma composicao portadora liquida a base de eter de celulose e de composicoes farmaceuticas que as contem
IE381991A IE65545B1 (en)	1990-11-22	1993-05-06	Liquid carrier composition
NO931852A NO307816B1 (no)	1990-11-22	1993-05-21	Geldannende, flytende bærermateriale, samt anvendelse av dette for fremstilling av et preparat
FI932325A FI103714B1 (fi)	1990-11-22	1993-05-21	Geeliä muodostava nesteväliainekoostumus
GR970400224T GR3022536T3 (en)	1990-11-22	1997-02-12	A gel-forming liquid carrier composition

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9003712A SE466134B (sv)	1990-11-22	1990-11-22	Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner

Publications (3)

Publication Number	Publication Date
SE9003712D0 SE9003712D0 (sv)	1990-11-22
SE9003712L SE9003712L (sv)	1992-01-07
SE466134B true SE466134B (sv)	1992-01-07

Family

ID=20380971

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9003712A SE466134B (sv)	1990-11-22	1990-11-22	Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner

Country Status (16)

Country	Link
US (1)	US5492937A (pt)
EP (1)	EP0558586B1 (pt)
JP (1)	JP2694166B2 (pt)
AT (1)	ATE147273T1 (pt)
AU (1)	AU660157B2 (pt)
CA (1)	CA2095728C (pt)
DE (1)	DE69124109T2 (pt)
DK (1)	DK0558586T3 (pt)
ES (1)	ES2095964T3 (pt)
FI (1)	FI103714B1 (pt)
GR (1)	GR3022536T3 (pt)
IE (1)	IE65545B1 (pt)
NO (1)	NO307816B1 (pt)
PT (1)	PT99593B (pt)
SE (1)	SE466134B (pt)
WO (1)	WO1992009307A1 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5324718A (en) *	1992-07-14	1994-06-28	Thorsteinn Loftsson	Cyclodextrin/drug complexation
US5472954A (en) *	1992-07-14	1995-12-05	Cyclops H.F.	Cyclodextrin complexation
US5981605A (en) *	1994-03-21	1999-11-09	John Brown Thomsen	Gel for treatment of skin diseases and for disinfection of the skin

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE466130B (sv) *	1990-11-22	1992-01-07	Kabi Pharmacia Ab	Gelbildande flytande dietfiberkomposition
US6440395B1 (en)	1992-06-22	2002-08-27	Barry M. Libin	Antiplaque mouth rinse
ATE204742T1 (de) *	1993-04-30	2001-09-15	Eastern Virginia Med School	Lokal anwendbares präparat zur reepithelisierung bei andauernden epitheldefekten
FR2710530B1 (fr) *	1993-09-29	1995-12-22	Phedon Zirinis	Gel aqueux à usage nasal, pellets, et leur procédé de préparation.
FR2710529A1 (fr) *	1993-09-29	1995-04-07	Zirinis Phedon	Gel aqueux à usage nasal, pellets, et leur procédé de préparation.
US5458879A (en) *	1994-03-03	1995-10-17	The Procter & Gamble Company	Oral vehicle compositions
DK0725628T3 (da) *	1994-08-30	2001-12-27	Alcon Lab Inc	Termisk geldannende lægemiddelindgivelsesvehikler indeholdende celluloseethere
US5827835A (en) *	1994-08-30	1998-10-27	Alcon Laboratories, Inc.	Thermally-gelling emulsions
US5976573A (en)	1996-07-03	1999-11-02	Rorer Pharmaceutical Products Inc.	Aqueous-based pharmaceutical composition
US5993787A (en) *	1996-09-13	1999-11-30	Johnson & Johnson Consumer Products, Inc.	Composition base for topical therapeutic and cosmetic preparations
US6117419A (en) *	1996-09-16	2000-09-12	Vernice; Joseph James	Delivery system for oil soluble actives in cosmetic/personal care products
DE19646392A1 (de)	1996-11-11	1998-05-14	Lohmann Therapie Syst Lts	Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US6108850A (en) *	1997-06-03	2000-08-29	Mclaughlin; Gerald	Accelerated method and instrumentation for whitening teeth
GB9712271D0 (en) *	1997-06-12	1997-08-13	Procter & Gamble	Cosmetic composition
GB9712269D0 (en) *	1997-06-12	1997-08-13	Procter & Gamble	Cosmetic composition
GB9712272D0 (en) *	1997-06-12	1997-08-13	Procter & Gamble	Cosmetic composition
US6316010B2 (en)	1997-06-12	2001-11-13	The Procter & Gamble Company	Cosmetic compositions
US6537537B2 (en)	1997-06-12	2003-03-25	The Procter & Gamble Company	Water-in-silicone emulsion cosmetic compositions
US6669927B2 (en)	1998-11-12	2003-12-30	3M Innovative Properties Company	Dental compositions
US6312667B1 (en)	1998-11-12	2001-11-06	3M Innovative Properties Company	Methods of etching hard tissue in the oral environment
US6312666B1 (en) *	1998-11-12	2001-11-06	3M Innovative Properties Company	Methods of whitening teeth
US6350472B1 (en)	1998-12-14	2002-02-26	Steinbach, Pylant, And Hermann, L.L.C.	Method of treating HIV infection with transdermal gel containing mammalian liver extract
US6156349A (en) *	1998-12-14	2000-12-05	Steinbach, Pylant And Herman, L.L.C.	Method of treating HIV infection with suppository containing mammalian liver extract
US6537575B1 (en) *	1999-07-30	2003-03-25	The University Of Chicago	Synthetic biological membrane with self organizing properties
JP2001329183A (ja) *	2000-05-22	2001-11-27	Yuichi Mori	ゲル化性組成物
US7674480B2 (en)	2000-06-23	2010-03-09	Teva Pharmaceutical Industries Ltd.	Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
JP2002154989A (ja) *	2000-11-14	2002-05-28	Lion Corp	眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
US6620405B2 (en)	2001-11-01	2003-09-16	3M Innovative Properties Company	Delivery of hydrogel compositions as a fine mist
US7714011B2 (en) *	2002-09-13	2010-05-11	Zicam, Llc	Compositions to reduce congestion and methods for application thereof to the nasal membrane
WO2004026953A1 (ja) *	2002-09-18	2004-04-01	Wakamoto Pharmaceutical Co.,Ltd.	透明な可逆性熱ゲル化水性組成物
US6953775B2 (en) *	2002-10-10	2005-10-11	Burruano Brid T	Composition for synthetic cervical mucus formulation
JP2004271361A (ja) *	2003-03-10	2004-09-30	Seiko Instruments Inc	携帯時計
US7051654B2 (en) *	2003-05-30	2006-05-30	Clemson University	Ink-jet printing of viable cells
SE0302924D0 (sv) *	2003-11-05	2003-11-05	Camurus Ab	Pharmaceutical composition having a cationic excipient
US8157788B2 (en) *	2003-11-06	2012-04-17	Paolo L. Manfredi	Multi-site drug delivery platform
US20050136112A1 (en) *	2003-12-19	2005-06-23	Pediamed Pharmaceuticals, Inc.	Oral medicament delivery system
US20050222539A1 (en) *	2004-03-30	2005-10-06	Pediamed Pharmaceuticals, Inc.	Automatic injection device
US8128952B2 (en) *	2005-01-12	2012-03-06	Clemson University Research Foundation	Ligand-mediated controlled drug delivery
SE530184C2 (sv) *	2005-12-23	2008-03-18	Kjell Stenberg	Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
US8480651B2 (en) *	2007-08-02	2013-07-09	Covidien Lp	Cannula system
FR2940761B1 (fr) *	2009-01-07	2012-12-28	Polymerexpert Sa	Composition anti-ronflement contenant un polymere thermogelifiant
US8916171B2 (en)	2010-04-27	2014-12-23	Topical Sinus Therapeutics, Inc.	Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis
EP2584994A1 (en) *	2010-06-24	2013-05-01	3M Innovative Properties Company	Aqueous composition suitable for intra-oral scanning methods
GB201105408D0 (en)	2011-03-30	2011-05-11	Glaxo Group Ltd	Composition
SE536091C2 (sv)	2011-04-14	2013-04-30	Pep Tonic Medical Ab	Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US11986491B2 (en) *	2011-06-22	2024-05-21	Iview Therapeutics, Inc.	Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
ES2685638T3 (es)	2011-07-26	2018-10-10	The Curators Of The University Of Missouri	Carne comestible producida artificialmente
GB201121300D0 (en) *	2011-12-12	2012-01-25	Glaxo Group Ltd	Novel composition
ES2375784B1 (es) *	2011-12-22	2013-01-24	Laboratorios Kin S.A.	Gel de ácido tranexámico
JP6039861B2 (ja) *	2013-07-17	2016-12-07	ダウグローバルテクノロジーズエルエルシー	ヒドロキシアルキルメチルセルロースを含む粘膜適用組成物
WO2015038988A1 (en)	2013-09-13	2015-03-19	Modern Meadow, Inc.	Edible and animal-product-free microcarriers for engineered meat
JP2017505138A (ja)	2014-02-05	2017-02-16	モダンメドーインコーポレイテッド	培養筋細胞から形成される乾燥食品
CA2953160C (en) *	2014-06-30	2023-10-17	Basf South East Asia Pte. Ltd.	Anti-agglomerants for polyisobutylene production
EP3180397A1 (en) *	2014-08-15	2017-06-21	Dow Global Technologies LLC	Ethylcellulose dispersion and powder
EP3337923B2 (en)	2015-09-21	2023-01-04	Modern Meadow, Inc.	Fiber reinforced tissue composites
JP7109882B2 (ja)	2016-02-15	2022-08-01	モダンメドウ，インコーポレイテッド	コラーゲンフィブリルを含むバイオファブリケーテッド材料を作製するための方法
SE1750680A1 (en)	2017-05-30	2018-12-01	Peptonic Medical Ab	Composition for treating or preventing climacteric disorders
AU2018253595A1 (en)	2017-11-13	2019-05-30	Modern Meadow, Inc.	Biofabricated leather articles having zonal properties
AU2020209847B2 (en)	2019-01-17	2024-10-17	Modern Meadow, Inc.	Layered collagen materials and methods of making the same
AU2021265055A1 (en)	2020-04-28	2022-12-15	Peptonic Medical Ab	Composition for treating and/or preventing vestibulodynia
EP4143258A4 (en)	2020-05-01	2024-05-22	Modern Meadow, Inc.	PROTEIN POLYURETHANE ALLOYS AND LAYERING MATERIALS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA529401A (en) *		1956-08-21	D. Klug Eugene	Modified ethyl cellulose and its method of preparation
US4042719A (en) *	1972-02-25	1977-08-16	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt	Compositions of low calory content
US4474753A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Topical drug delivery system utilizing thermosetting gels
US4474752A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
US4474751A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Ophthalmic drug delivery system utilizing thermosetting gels
US4478822A (en) *	1983-05-16	1984-10-23	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
US4795327A (en) *	1984-03-26	1989-01-03	Forest Laboratories, Inc.	Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
AU598588B2 (en) *	1986-09-01	1990-06-28	Terumo Kabushiki Kaisha	Food composition
SE461396B (sv) *	1988-05-24	1990-02-12	Berol Kemi Ab	Saett att vid temperaturhoejning motverka viskositetsnedgaang alternativt aastadkomma viskositetsoekning hos ett vattenbaserat system innehaallande en polymer som viskositetsgivare
EP0386960A3 (en) *	1989-03-07	1991-10-23	American Cyanamid Company	Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
SE466130B (sv) *	1990-11-22	1992-01-07	Kabi Pharmacia Ab	Gelbildande flytande dietfiberkomposition

1990
- 1990-11-22 SE SE9003712A patent/SE466134B/sv not_active IP Right Cessation
1991
- 1991-10-30 AT AT91920627T patent/ATE147273T1/de not_active IP Right Cessation
- 1991-10-30 WO PCT/SE1991/000731 patent/WO1992009307A1/en not_active Ceased
- 1991-10-30 JP JP4500094A patent/JP2694166B2/ja not_active Expired - Fee Related
- 1991-10-30 DE DE69124109T patent/DE69124109T2/de not_active Expired - Fee Related
- 1991-10-30 US US08/064,141 patent/US5492937A/en not_active Expired - Fee Related
- 1991-10-30 ES ES91920627T patent/ES2095964T3/es not_active Expired - Lifetime
- 1991-10-30 CA CA002095728A patent/CA2095728C/en not_active Expired - Fee Related
- 1991-10-30 EP EP91920627A patent/EP0558586B1/en not_active Expired - Lifetime
- 1991-10-30 DK DK91920627.6T patent/DK0558586T3/da active
- 1991-10-30 AU AU89543/91A patent/AU660157B2/en not_active Ceased
- 1991-11-22 PT PT99593A patent/PT99593B/pt active IP Right Grant
1993
- 1993-05-06 IE IE381991A patent/IE65545B1/en not_active IP Right Cessation
- 1993-05-21 NO NO931852A patent/NO307816B1/no not_active IP Right Cessation
- 1993-05-21 FI FI932325A patent/FI103714B1/fi active
1997
- 1997-02-12 GR GR970400224T patent/GR3022536T3/el unknown

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5324718A (en) *	1992-07-14	1994-06-28	Thorsteinn Loftsson	Cyclodextrin/drug complexation
US5472954A (en) *	1992-07-14	1995-12-05	Cyclops H.F.	Cyclodextrin complexation
US5981605A (en) *	1994-03-21	1999-11-09	John Brown Thomsen	Gel for treatment of skin diseases and for disinfection of the skin
US6342537B1 (en)	1994-03-21	2002-01-29	John Brown Thomsen	Gel for treatment of skin diseases and for disinfection of the skin

Also Published As

Publication number	Publication date
PT99593B (pt)	2000-08-31
SE9003712L (sv)	1992-01-07
CA2095728A1 (en)	1992-05-23
EP0558586A1 (en)	1993-09-08
GR3022536T3 (en)	1997-05-31
FI932325L (fi)	1993-05-21
JP2694166B2 (ja)	1997-12-24
ES2095964T3 (es)	1997-03-01
ATE147273T1 (de)	1997-01-15
AU660157B2 (en)	1995-06-15
DE69124109D1 (de)	1997-02-20
IE913819A1 (en)	1992-06-03
WO1992009307A1 (en)	1992-06-11
AU8954391A (en)	1992-06-25
US5492937A (en)	1996-02-20
JPH06505705A (ja)	1994-06-30
PT99593A (pt)	1992-10-30
NO307816B1 (no)	2000-06-05
DK0558586T3 (da)	1997-01-27
FI103714B (fi)	1999-08-31
NO931852L (no)	1993-07-21
FI932325A0 (fi)	1993-05-21
CA2095728C (en)	2002-01-22
IE65545B1 (en)	1995-11-01
SE9003712D0 (sv)	1990-11-22
DE69124109T2 (de)	1997-06-19
EP0558586B1 (en)	1997-01-08
FI103714B1 (fi)	1999-08-31
NO931852D0 (no)	1993-05-21

Legal Events

Date

Code

Title

Description

1995-01-31

NAL

Patent in force

Ref document number: 9003712-8

Format of ref document f/p: F

2005-07-05

NUG

Patent has lapsed

Publication	Publication Date	Title
SE466134B (sv)	1992-01-07	Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner
US5876744A (en)	1999-03-02	Highly bioadhesive and mucoadhesive compositions containing polyvinyl alcohol, polycarbophil and biopolymer for the treatment of skin conditions and as vehicles for active ingredients
Ahuja et al.	1997	Mucoadhesive drug delivery systems
Tan et al.	2000	Effect of Carbopol and polyvinylpyrrolidone on the mechanical, rheological, and release properties of bioadhesive polyethylene glycol gels
DE69429048T2 (de)	2002-07-11	Biologisch erodierbare Vorrichtung zur Verabreichung von Wirkstoffen
Tuğcu-demiröz	2017	Development of in situ poloxamer-chitosan hydrogels for vaginal drug delivery of benzydamine hydrochloride: Textural, mucoadhesive and in vitro release properties
JPS6160620A (ja)	1986-03-28	ピログルタミン酸エステル類を含有する医薬品組成物
JPH10508833A (ja)	1998-09-02	痔核用組成物および使用方法
KR20010031828A (ko)	2001-04-16	Ｎｓａｉ 약물 전달을 위한 국소 투여용 조성물
Amal et al.	2015	Preparation of artificial saliva formulation
CN101919806A (zh)	2010-12-22	活性物质的冻干组合物
KR100943105B1 (ko)	2010-02-18	다당류 함유 조성물 및 그의 용도
JPH09508898A (ja)	1997-09-09	体液の代用および／または補充のための治療的組成物
EP1807114B1 (fr)	2008-08-06	Composition bioadhesive a liberation programmee
CN110074996A (zh)	2019-08-02	一种具有液晶结构的保湿面膜及其制备方法
EP3222270A1 (en)	2017-09-27	Compositions for mucosal adhesion and uses thereof
KR102224224B1 (ko)	2021-03-08	식용 가능한 시트형 물품
JP4263418B2 (ja)	2009-05-13	熱ゲル化人工涙液
JP2004168725A (ja)	2004-06-17	皮膚外用水性組成物
Mutta	2021	A Review on Emulgel
Zhang	2005	A Bio-Adhesive Formulation for the Delivery of Anti-Fungal Agents to the Oesophagus
AU2012200105B2 (en)	2014-11-20	Bioadhesive composition with programmed release
BG65734B1 (bg)	2009-09-30	Течен мукоадхезивен фармацевтичен състав
JPS6377814A (ja)	1988-04-08	潤滑剤
JP2004292370A (ja)	2004-10-21	水性スティック状化粧料